************************************
Brakke Consulting’s
Animal Health News & Notes for November 19, 2010
Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon, DVM MBA
************************************
IN THE NEWS:
Brakke news
2010 Flea Study
earnings news
Alpharma
Animal Health International
Heska
PetMed Express
PetSmart
other news
Animalcare
Aurora Pharmaceuticals
Bayer
Blazer Labs
GenomIdea
Helia Medical
Meiji Seika Kaisha
Petmate
Piedmont Pharmaceuticals
Quincy Animal Health
Teva
Vetoquinol
Vical
***********************************
COMING SOON!
US FLEA CONTROL AND HEARTWORM MARKETS
2010 UPDATE
LAST CHANCE FOR EARLY-BIRD DISCOUNT
Brakke Consulting will soon be publishing our 2010 report on the US Flea Control and Heartworm Markets. The report includes valuable information on the US market for small animal parasiticides including:
– an overview of the veterinary and OTC flea control markets
– Product descriptions, prices, and sales for the leading veterinary flea and heartworm products
The report also includes a 2010 survey of over 200 veterinarians regarding topics such as product usage, brand switching, the effect of the economy on product sale; the impact of product sales outside the veterinary clinic channel; and developing resistance to new-generation products.
The report on the US Flea Control & Heartworm Markets will be available for a purchase price of $4,995 if ordered by WEDNESDAY, NOVEMBER 24, and $5,500 after that date.
Please contact Dr. Lynn Fondon at (972) 243-4033 or lfondon@brakkeconsulting.com to pre-order the report, or for more information visit our website at www.BrakkeConsulting.com
************************************
COMPANY EARNINGS RELEASES
> King Pharmaceuticals reported results for the third quarter of 2010. Revenues for Alpharma Animal Health were $93 million, a decline of 3% compared to the third quarter of 2009. (company website)
> Heska reported results for the third quarter of 2010. Total revenues were $17.6 million, down 10% compared to the third quarter of 2010. Net income for the quarter was $241,000 compared to $743,000 in the comparable period in the prior year. (company press release)
> Animal Health International, Inc. reported its financial results for the Company’s first fiscal quarter ended September 30, 2010. Net sales increased 9%, to $177 million, compared to $161 million for the same period a year ago. Net loss was ($0.5 million) compared to a loss of ($0.7 million) in last year’s first quarter. (company website)
> PetSmart, Inc. reported results for the third quarter of 2009. Total sales for the third quarter of 2010 increased 7% to $1.4 billion. Net income totaled $45.6 million in the third quarter of 2010, compared to $38.1 million in the third quarter of 2009. (company website)
> PetMed Express, Inc. announced its financial results for the quarter ended September 30, 2010. Net sales for the quarter were $61 million, a decrease of 2% compared to the quarter ended September 30, 2009. Net income was $5.0 million, a 21% decrease. (company website)
************************************
COMPANY NEWS RELEASES
> Bayer announced the acquisition of an innovative chewable application technology from Piedmont Pharmaceuticals. In addition, Bayer will get access to two products in late-stage development at Piedmont. Financial terms were not disclosed. (www.finchannel.com)
> Teva Animal Health announced the return of its DVM Feline Joint Gel to the veterinary market. The re-launch of DVM feline Joint Gel comes after the October introduction of two new nutritional supplements to support digestive health: Endurosyn Oral Gel and Lactoquil Chewable Tablets. (company press release)
> Aurora Pharmaceuticals announced the launch of Barrier Wound Care Spray for cattle and swine. The spray is a 2% titratable iodine that contains lidocaine and a natural anti-chewing agent. (company press release)
> Blazer Labs announced an exclusive sales agreement wherein Blazer will market Helia Medical’s new Stomatitis Treatment Kit for Cats and Once and Done Treatment Kit for chronic otitis in dogs. Both products utilize an FDA-approved nanoparticle technology designed to eliminate bacteria and fungi and to neutralize viruses. (company press release)
> Quincy Animal Health announce the launch of Neutricks, a chewable supplement for aging dogs exhibiting signs of Cognitive Dysfunction Syndrome (CDS), to the veterinary marketplace. Neutricks contains the jellyfish protein “apoaequorin.” (company press release)
> Petmate announced a partnership with Pet Airways, the first airline specifically designed to transport pets. Petmate is now the sole provider of carriers for Pet Airways. (PRNewswire)
> UK Animalcare announced the UK launch of Florgane aqueous suspension for injection, a novel florfenicol presentation for bovine respiratory disease. (company website)
> JAPAN Vetoquinol announced it has obtained Marketing Authorization from Japanese drug authorities for its Marbocyl 2% and Marbocyl 10% antibiotics for livestock, through collaboration with Meiji Seika Kaisha, Ltd. (Business Wire)
> JAPAN Vical Incorporated announced that the company has entered into an evaluation and supply agreement with GenomIdea Inc., a subsidiary of AnGes MG, Inc., for the development of a DNA vaccine for livestock against pandemic influenza. Vical will provide the company’s H1N1 influenza vaccine know-how, as well as evaluation supplies of the company’s Vaxfectin adjuvant. GenomIdea will manufacture the DNA vaccine and evaluate its efficacy in animals, including swine, with Vical’s Vaxfectin adjuvant. If successful, GenomIdea intends to commercialize the resulting product as a livestock vaccine. (GlobeNews)
***********************************
ANIMAL HEALTH NEWS
> US – ANIMAL SAFETY A new National Research Council (NRC) report requested by Congress finds “several major shortcomings” in a US Department of Homeland Security assessment of risks associated with operating the proposed National Bio & Agro-Defense Facility (NBAF) in Manhattan, Kansas. Based on the DHS risk assessment reviewed by the NRC committee, there is nearly a 70% chance over the 50-year lifetime of the facility that a release of foot-and-mouth disease could result in an infection outside the laboratory, with an estimated effect to the economy of $9 billion to $50 billion. Pre-publication copies of “Evaluation of a Site-Specific Risk Assessment for the Department of Homeland Security’s Planned National Bio- & Agro-Defense Facility in Manhattan, Kansas” are available from the National Academies Press at http://www.nap.edu. (Feedstuffs)
************************************
BRAKKE CONSULTING VIEWPOINT
The revenues and profits being reported in this week’s newsletter are a bit of a mixed bag. These reports point out the relative difficulty or strength of the market channels and/or species being served. Companion animal sectors have remained generally strong, or at least less challenging, in 2010 compared to the food animal sectors. All the reports that we’re reading suggest that corn is likely to remain above the $5 per bushel level for some time. The high corn prices have negative impacts that flow down from the producer to the suppliers. If it hits $7 or $8 per bushel and stays there for long, we’ll have a disaster on our hands in the whole economy.
We expect by now that many of you have already departed for a few days off during US Thanksgiving holiday week. We want to take this opportunity to thank all of our clients, newsletter readers, consultants and friends for your support during 2010. It’s been another great year for Brakke Consulting. Though there are a few storm clouds on the horizon for 2011 we continue to be optimistic regarding the future of animal health as an industry. We want to wish our US readers a safe and enjoyable Thanksgiving holiday week. Make a contribution by eating your share of animal protein this coming week!
Have a great weekend!!
Ron Brakke
************************************
This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at www.brakkeconsulting.com.
Brakke Consulting, Inc.
2735 Villa Creek, Suite 140
Dallas, TX 75234 USA
English (United States) 
Portuguese